down arrow

Homology Medicines, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4380831077
USD
3.62
0.21 (6.16%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.263.75

52 Week

1.3528.06
Valuation
Technical
Day's Volume

CASH

230.02 k

Shareholding (Mar 2025)

FII

24.11%

Held by 41 FIIs

DII

0

Held by 17 DIIs

Promoter

60.47%

How big is Homology Medicines, Inc.?

22-Jun-2025

As of Jun 18, Homology Medicines, Inc. has a market capitalization of 19.73 million, with net sales of 0.00 million and a net profit of -59.79 million over the last four quarters. The company reported shareholder's funds of 5.67 million and total assets of 92.33 million as of Dec 24.

Market Cap: As of Jun 18, Homology Medicines, Inc. has a market capitalization of 19.73 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Homology Medicines, Inc. reported net sales of 0.00 million and a net profit of -59.79 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 5.67 million and total assets of 92.33 million.

Read More

What does Homology Medicines, Inc. do?

22-Jun-2025

Homology Medicines, Inc. is a micro-cap genetic medicines company focused on developing gene editing and gene therapy treatments for rare diseases. As of March 2025, it reported a net profit loss of $11 million and has a market cap of $19.73 million.

Overview: <BR>Homology Medicines, Inc. is a genetic medicines company focused on developing gene editing and gene therapy treatments for rare diseases within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 19.73 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 12.99 <BR>Return on Equity: 1,455.21% <BR>Price to Book: -4.92<BR><BR>Contact Details: <BR>Address: 1 Patriots Park, BEDFORD MA: 01730-2343 <BR>Tel: 1 781 3017277 <BR>Fax: 1 302 6555049 <BR>Website: https://www.homologymedicines.com/

Read More

Who are in the management team of Homology Medicines, Inc.?

22-Jun-2025

As of March 2022, the management team of Homology Medicines, Inc. is led by Dr. Arthur Tzianabos as President and CEO, alongside independent directors Mr. Jeffrey Poulton, Mr. Steven Gillis, Dr. Richard Gregory, Dr. Kush Parmar, and Mr. Matthew Patterson.

As of March 2022, the management team of Homology Medicines, Inc. includes Dr. Arthur Tzianabos, who serves as the President, Chief Executive Officer, and Director. Additionally, the Board of Directors features Mr. Jeffrey Poulton, Mr. Steven Gillis, Dr. Richard Gregory, Dr. Kush Parmar, and Mr. Matthew Patterson, all of whom are independent directors. <BR><BR>In summary, the key members of the management team are Dr. Arthur Tzianabos and the independent directors listed above.

Read More

Is Homology Medicines, Inc. overvalued or undervalued?

25-Jun-2025

As of February 9, 2024, Homology Medicines, Inc. is rated as "does not qualify" due to being overvalued at $1.53, with a negative price-to-book value of -5.77 and a significant decline of 90.12% against the S&P 500 over the past year, despite a high ROCE of 113.04%.

As of 9 February 2024, the valuation grade for Homology Medicines, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently assessed as overvalued, particularly given its negative price-to-book value of -5.77 and a high return on capital employed (ROCE) of 113.04%, which suggests inefficiencies in capital utilization despite high returns.<BR><BR>In comparison to its peers, Homology Medicines shows a stark contrast with G1 Therapeutics, Inc. and ADC Therapeutics SA, both rated as risky with P/E ratios of -8.43 and -2.10, respectively. The EV to EBITDA ratio for Homology is 0.46, which is more favorable than some peers, but the overall financial health and performance metrics suggest that the stock is not justified at its current price of $1.53, especially considering its drastic underperformance against the S&P 500 over the past year, where it has declined by 90.12%.

Read More

Is Homology Medicines, Inc. technically bullish or bearish?

20-Sep-2025

As of August 21, 2025, Homology Medicines, Inc. shows a mildly bearish trend with mixed technical indicators, including mildly bullish MACD signals but bearish daily moving averages, and has significantly underperformed the S&P 500 with a year-to-date return of -49.42%.

As of 21 August 2025, the technical trend for Homology Medicines, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the weekly RSI is bearish, contrasting with a bullish monthly RSI, suggesting mixed signals across time frames. The daily moving averages are bearish, further supporting the mildly bearish stance. Additionally, the Bollinger Bands are bearish on a weekly basis and mildly bearish monthly. <BR><BR>Overall, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -49.42% versus the S&P 500's 12.22%, and a one-year return of -96.25% compared to the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 22 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

3.39

stock-summary
Return on Equity

411.30%

stock-summary
Price to Book

-1.81

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-9 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
111.7%
0%
111.7%
6 Months
88.54%
0%
88.54%
1 Year
-85.38%
0%
-85.38%
2 Years
-62.83%
0%
-62.83%
3 Years
139.74%
0%
139.74%
4 Years
-95.54%
0%
-95.54%
5 Years
-62.95%
0%
-62.95%

Homology Medicines, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Homology Medicines, Inc. technically bullish or bearish?

As of 21 August 2025, the technical trend for Homology Medicines, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the weekly RSI is bearish, contrasting with a bullish monthly RSI, suggesting mixed signals across time frames. The daily moving averages are bearish, further supporting the mildly bearish stance. Additionally, the Bollinger Bands are bearish on a weekly basis and mildly bearish monthly. Overall, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -49.42% versus the S&P 500's 12.22%, and a one-year return of -96.25% compared to the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
9.52%
EBIT to Interest (avg)
-96.93
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
12.99
Sales to Capital Employed (avg)
0.02
Tax Ratio
0.04%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-5.77
EV to EBIT
0.46
EV to EBITDA
0.46
EV to Capital Employed
0.52
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
113.04%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 20 Schemes (15.49%)

Foreign Institutions

Held by 41 Foreign Institutions (24.11%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 13.64% vs 22.54% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.10",
          "val2": "-12.10",
          "chgp": "24.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "-1.50",
          "chgp": "60.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.50",
          "val2": "-11.00",
          "chgp": "13.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 100.00% vs -309.38% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 11.17% vs -974.00% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "-6.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-65.60",
          "val2": "-47.80",
          "chgp": "-37.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "1.50",
          "chgp": "-80.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "17.40",
          "val2": "-6.20",
          "chgp": "380.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-47.70",
          "val2": "-53.70",
          "chgp": "11.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-9.10
-12.10
24.79%
Interest
0.30
0.30
Exceptional Items
-0.60
-1.50
60.00%
Consolidate Net Profit
-9.50
-11.00
13.64%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 13.64% vs 22.54% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
-6.70
100.00%
Operating Profit (PBDIT) excl Other Income
-65.60
-47.80
-37.24%
Interest
0.30
1.50
-80.00%
Exceptional Items
17.40
-6.20
380.65%
Consolidate Net Profit
-47.70
-53.70
11.17%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 100.00% vs -309.38% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 11.17% vs -974.00% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Homology Medicines, Inc. stock-summary
stock-summary
Homology Medicines, Inc.
Pharmaceuticals & Biotechnology
Homology Medicines, Inc. is a genetic medicines company translating gene editing and gene therapy technology into treatments for patients with rare diseases. The Company is focused on developing a pipeline of new medicines that address and cure the underlying cause of monogenic diseases in the liver, central nervous system (CNS), bone marrow, lung and the eye. The Company’s lead product candidate, HMI-102 is a gene therapy for the treatment of phenylketonuria (PKU). Its PKU program is focused on adults using the gene therapy approach. The Company’s suite of 15 adeno-associated virus vectors (AAVHSCs) enables it to focus on a method of gene editing called gene correction. The Company’s diverse set of AAVHSCs allows it to precisely target, via a single intravenous injection, a wide range of disease-relevant tissues, including the liver, central nervous system, or CNS, bone marrow, lung, muscle and eye, across both modalities - gene editing and gene therapy.
Company Coordinates stock-summary
Company Details
1 Patriots Park , BEDFORD MA : 01730-2343
stock-summary
Tel: 1 781 3017277
stock-summary
https://www.homologymedicines.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."